Patents Examined by Kara R McMillian
  • Patent number: 10238644
    Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: March 26, 2019
    Assignee: Medicis Pharmaceutical Corporation
    Inventors: Michael T. Nordsiek, Sharon F. Levy, James Hurn-Joung Lee, James H. Kulp, Kodumudi S. Balaji, Tze-Chiang Meng, Jason J. Wu, Valyn S. Bahm, Robert Babilon
  • Patent number: 10166232
    Abstract: The present invention discloses ophthalmic and otic compositions of facially amphiphilic antimicrobial polymers and oligomers and their uses, including their use in methods for treating and preventing ophthalmic infections and otic infections in humans and animals.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: January 1, 2019
    Assignee: Innovation Pharmaceuticals Inc.
    Inventor: Richard W. Scott
  • Patent number: 10130714
    Abstract: Novel dual-targeted, bifunctional anti-influenza drugs formed by conjugation with anti-inflammatory agents are disclosed. Exemplary drugs according to the invention include caffeic acid (CA)-bearing zanamivir (ZA) conjugates ZA-7-CA (1), ZA-7-CA-amide (7) and ZA-7-Nap (43) for simultaneous inhibition of influenza virus neuraminidase and suppression of proinflammatory cytokines. Synthetic methods for preparation of these enhanced anti-influenza conjugate drugs are provided. The synthetic bifunctional ZA conjugates act synergistically towards protection of mice lethally infected by H1N1 or H5N1 influenza viruses. The efficacy of ZA-7-CA, ZA-7-CA-amide and ZA-7-Nap conjugates is much greater than the combination therapy of ZA with anti-inflammatory agents.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: November 20, 2018
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Jim-Min Fang, Kung-Cheng Liu, Jia-Tsrong Jan, Yih-Shyun E. Cheng, Ting-Jen R. Cheng
  • Patent number: 10130602
    Abstract: The invention relates to the use of L-carnitine, a salt of L-carnitine, a derivative of L-carnitine and/or salt of a derivative of L-carnitine, as well as respective methods and compositions, for reducing or preventing fatigue and/or for improving cognitive function in an animal. The animal is preferably a healthy individual and the use is preferably a non-therapeutic use.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: November 20, 2018
    Assignee: Lonza Ltd.
    Inventors: Adriana Williams, Frauke Warrikoff, Ulla Freitas, Richard Sasse, Kevin Owen
  • Patent number: 10111855
    Abstract: Equol (7-hydroxy-3(4?hydroxyphenyl)-chroman), or metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5?-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: October 30, 2018
    Assignees: Brigham Young University, Colorado State University Research Foundation
    Inventors: Edwin Douglas Lephart, Trent D. Lund, Robert J. Handa
  • Patent number: 10105356
    Abstract: Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: October 23, 2018
    Assignee: Avalyn Pharma Inc.
    Inventor: Mark William Surber
  • Patent number: 10092552
    Abstract: Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: October 9, 2018
    Assignee: AVALYN PHARMA INC.
    Inventor: Mark William Surber
  • Patent number: 10071066
    Abstract: Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: September 11, 2018
    Assignee: Duke University
    Inventors: Suzanne E. Wardell, Erik R. Nelson, Donald P. McDonnell
  • Patent number: 10059689
    Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.
    Type: Grant
    Filed: October 10, 2015
    Date of Patent: August 28, 2018
    Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Ning Xi, Minxiong Li, Xiaobo Li, Weilong Dai, Haiyang Hu, Tao Zhang, Wuhong Chen
  • Patent number: 10039747
    Abstract: The present invention provides tetrahydrocyclopentapyrrole derivatives that can be used for preventing or treating peptic ulcer, gastritis or reflux esophagitis, a method for preparing the same, and a pharmaceutical composition containing the same.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: August 7, 2018
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Kyung A Yu, Ji Sung Yoon, Deok Ki Eom, Yeon Im Lee, Mi Ryeong Han, Jun Hee Lee, Ha Nee Seo, Ji Duck Kim, Sang Ho Lee
  • Patent number: 10039722
    Abstract: Methods of treating or suppressing oxidative stress diseases and symptoms related to oxidative stress affecting normal electron flow in the cells or caused by reactive oxygen species with redox-active therapeutics. Use of redox-active therapeutics for the reduction, suppression or treatment of oxidative stress induced by chemical agents such as contrast agents and other nephrotoxic agents, by radiation exposure, and by disruptions in the transport of oxygen to tissues, is disclosed.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: August 7, 2018
    Assignee: BIOELECTRON TECHNOLOGY CORPORATION
    Inventor: Guy M. Miller
  • Patent number: 10039764
    Abstract: Disclosed are methods for treating cancer and precancerous conditions with PDE10A specific inhibitors and diagnosis of neoplastic diseases based on elevated levels of PDE10A.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: August 7, 2018
    Assignee: University of South Alabama
    Inventor: Gary A. Piazza
  • Patent number: 9968591
    Abstract: Disclosed is a pharmaceutical composition for antifungal use, comprising: 1) one or more compounds selected from compounds represented by the general formula (1) below and physiologically acceptable salts thereof; 2) one or more compounds selected from polypropylene glycol, diesters of dibasic acids, triacetin, 2-ethyl-1,3-hexanediol, lauromacrogol, and polyoxyethylene-polyoxypropylene glycol; and 3) one or more compounds selected from glucono-?-lactone, propylene glycol, glycerin, and lactic acid. General formula (1) (In the formula, X represents a halogen or hydrogen). wherein X represents a halogen or hydrogen.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: May 15, 2018
    Assignees: Pola Pharma Inc., Nihon Nohyaku CO., LTD.
    Inventors: Takaaki Masuda, Naoto Nishida, Naoko Kobayashi, Hideaki Sasagawa
  • Patent number: 9962362
    Abstract: Inhibitors of EYA tyrosine phosphatase are provided herein, as well as pharmaceutical compositions and methods relating thereto.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: May 8, 2018
    Assignee: Children's Hospital Medical Center
    Inventor: Rashmi Hegde
  • Patent number: 9949981
    Abstract: The present invention relates to methods of treating cell proliferative disorders, such as cancer or Proteus syndrome, by utilizing 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine or 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-(3-morpholinophenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine or N-(1-(3-(3-(4-(1-aminocyclobutyl)phenyl)-2-(2-aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-5-yl)phenyl)piperidin-4-yl)-N-methylacetamide. The methods of the present invention can also relate to methods of treating cell proliferative disorders, such as cancer or Proteus syndrome, by utilizing the above compounds in combination with ((R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine).
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: April 24, 2018
    Assignee: ArQule, Inc.
    Inventors: Daniel T. Dransfield, Sudharshan Eathiraj, Jean-Marc Lapierre, Brian Schwartz, Yi Yu
  • Patent number: 9931353
    Abstract: The present invention relates to a method for treating an individual having Cerebral Amyloid Angiopathy by using pharmacological chaperones to increase the activity of gangliosidase and/or sialidase enzymes involved in ganglioside catabolism.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: April 3, 2018
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Brandon Alan Wustman, Kenneth Valenzano, Robert Boyd
  • Patent number: 9901578
    Abstract: The present invention relates to compositions comprising a combination of 10-propargyl-10-deazaaminopterin and an EGFR Kinase inhibitor, including erlotinib, for treatment of non-small cell lung cancer, and methods of treatment for non-small cell lung cancer in a patient in need thereof comprising administering for combination of 10-propargyl-10-deazaaminopterin and an EGFR Kinase inhibitor, including erlotinib, for treatment of non-small cell lung cancer.
    Type: Grant
    Filed: July 17, 2013
    Date of Patent: February 27, 2018
    Assignee: ALLOS THERAPEUTICS, INC.
    Inventor: Gijsbertus J. Pronk
  • Patent number: 9889116
    Abstract: Equol (7-hydroxy-3(4?hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5?-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: February 13, 2018
    Assignees: BRINGHAM YOUNG UNIVERSITY, COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Edwin Douglas Lephart, Trent D. Lund, Robert J. Handa
  • Patent number: 9834738
    Abstract: The present invention is directed to a novel fragrance compound of octahydro-4,7-methano-1H-indene-5-acetaldehyde.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: December 5, 2017
    Inventors: Anubhav P. S. Narula, James Anthony Lasome, Richard A. Weiss, Michael G. Monteleone
  • Patent number: 9789119
    Abstract: Provided herein are methods, drug formulations, and dosing regimens for improving cognitive function in a normal or cognitively impaired subject. For instance, methods provided herein comprise administering a GABAA receptor antagonist so that peak concentration of the GABAA receptor antagonist occurs when the subject is asleep.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: October 17, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Craig C. Garner, H Craig Heller, Damien Colas, Daniel Z. Wetmore